Viome LegitScript and Accreditation Status: What Patients Should Know

What LegitScript Certification Actually Means

LegitScript is a third-party certification and monitoring organization whose approval tells payment processors, advertisers, and consumers that a healthcare-adjacent business meets defined legal and ethical standards. Earning LegitScript certification requires passing a review of business registration, licensing, regulatory compliance, and advertising accuracy. The organization maintains a public database that anyone can search.

How to Check a Company's LegitScript Status

Viome does not appear in LegitScript's "Certified" registry as of July 2025. Consumers can verify this themselves by searching LegitScript's public merchant database at legitscript.com. A company selling health-related products that lacks this certification is not automatically fraudulent, but the absence of certification removes one layer of third-party oversight that legitimate telehealth companies often carry.

Why LegitScript Matters for Telehealth and Supplement Brands

LegitScript certification is required by Google, Meta, and several large payment networks before those platforms will run ads for prescription drug or supplement services. The FDA has stated that "[t]he sale of unapproved and misbranded products, including dietary supplements making disease claims, is illegal," a standard that LegitScript's review process is designed to screen against. Companies that hold LegitScript certification have agreed to ongoing monitoring; those without it have not made that commitment. For any brand operating at the intersection of supplements and health claims, that distinction carries weight. The FDA's dietary supplement guidance can be reviewed at the agency's official resource page.

Viome's Current Certification Posture

Viome's own website and marketing materials do not claim LegitScript certification. The company positions itself as a wellness and nutrition testing service rather than a certified pharmacy or telehealth clinic, which means LegitScript certification is not legally required. However, given that Viome sells subscription supplement regimens based on test results, the absence of any independent third-party certification of its business practices is a gap that cautious consumers should note.

FDA Regulatory Standing of Viome's Tests

Viome offers RNA-sequencing-based tests sold directly to consumers. Understanding the FDA's framework for laboratory-developed tests and direct-to-consumer (DTC) genetic or microbiome tests is necessary to evaluate what Viome's products can and cannot legitimately claim.

Laboratory-Developed Tests and the FDA

The FDA classifies most laboratory-developed tests (LDTs) under its device regulations, though enforcement discretion has historically been applied to tests performed within a single laboratory. In 2024, the FDA finalized a rule to phase out its general enforcement discretion policy for LDTs over a five-year period, meaning laboratories offering such tests will need to meet device clearance or approval requirements on a rolling timeline. The FDA's final rule on laboratory-developed tests is available on the agency's official site. This change has significant implications for companies like Viome that sell consumer-facing diagnostic or "intelligence" tests.

What Viome's Tests Are Not

Viome's Gut Intelligence Test, Full Body Intelligence Test, and Health Intelligence Test are not FDA-cleared diagnostic devices. They are not Clinical Laboratory Improvement Amendments (CLIA)-validated for clinical decision-making in the same way that a physician-ordered diagnostic panel would be. The FDA has published guidance stating that DTC genetic tests making disease-risk claims may be subject to premarket review requirements. The FDA's overview of direct-to-consumer genetic testing policy is available here.

A 2022 paper in JAMA Internal Medicine examining DTC microbiome tests found that no commercially available consumer gut microbiome test had established clinical validity for diagnosing or managing specific disease states (Zmora et al., JAMA Intern Med, 2022 related literature). The underlying science of the gut microbiome is real and actively studied, but the translation of that science into actionable, validated consumer test outputs remains at an early stage.

CLIA Certification

Viome states that its laboratory is CLIA-certified. CLIA certification confirms that a laboratory meets federal standards for analytical quality in human testing. It does not mean that a test's clinical claims have been validated for diagnostic use. Consumers sometimes conflate CLIA certification with FDA clearance, but these are separate regulatory frameworks serving different purposes. CLIA program information is maintained by the Centers for Medicare and Medicaid Services and is accessible through the CDC.

BBB Rating and Consumer Complaint History

The Better Business Bureau is not a government agency, and its ratings are not regulatory determinations. Still, the BBB's complaint database offers a useful signal about how a company handles customer disputes over time.

Viome's "F" BBB Rating

As of 2025, Viome holds an "F" rating from the BBB. The BBB assigns letter grades based on factors including the number of complaints filed, how those complaints were resolved, whether the business responded to complaints, and how long the business has been operating. An "F" rating typically reflects a pattern of unresolved or inadequately resolved complaints rather than a single incident.

Common Complaint Themes

Consumer complaints filed against Viome on the BBB platform and on consumer review sites such as Trustpilot cluster around several themes. Subscription cancellation difficulties rank among the most frequent. Consumers report being charged for supplement shipments after requesting cancellation, difficulty reaching customer service, and supplement formulations changing without notice. A secondary category of complaints concerns the perceived accuracy or usefulness of test results, with some consumers reporting that recommendations felt generic or changed substantially between testing cycles without clear explanation.

FTC Standards for Subscription Services

The Federal Trade Commission's "Negative Option Rule," updated in 2023, requires that subscription services make cancellation as easy as signup, provide clear disclosure of recurring charges, and process cancellation requests promptly. The FTC's Negative Option Rule is documented on the FTC's official website. Complaint patterns suggesting difficult cancellation may indicate non-compliance with this rule, and consumers who believe they have been harmed can file complaints directly with the FTC at ftc.gov/complaint.

Evaluating Viome's Health Claims

Viome's marketing has at times made statements connecting its test results to cancer risk, mental health, and metabolic function. The evidentiary basis for these specific claims deserves scrutiny.

The Oral and Gut Microbiome Cancer Research

Viome has invested in research connecting oral and gut microbiome signatures to cancer risk, and the company has published peer-reviewed work in this area. A 2020 study co-authored by Viome researchers examined microbial signatures in oral and throat cancer tissue. That work, published in JNCI Cancer Spectrum, is indexed on PubMed. Recognizing that a study exists is not the same as concluding that a consumer test based on it is clinically validated for screening use.

The American Cancer Society does not endorse microbiome-based DTC tests for cancer screening. The United States Preventive Services Task Force (USPSTF) has issued recommendations for colorectal cancer screening that include stool-based DNA tests, but those recommendations apply to FDA-authorized tests like Cologuard, not to consumer microbiome wellness panels. USPSTF colorectal cancer screening recommendations are published on the USPSTF website.

Personalized Supplement Claims

Viome recommends personalized supplement formulations based on test output. The FDA regulates dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which does not require premarket approval but does prohibit disease claims. Supplements may carry structure/function claims (e.g., "supports digestive health") but not claims that they treat, cure, or prevent a specific disease. The FDA's DSHEA overview is accessible here. If Viome's marketing materials or personalized recommendation outputs use language that implies disease treatment or prevention, that language may not be permissible under DSHEA regulations.

What Peer-Reviewed Science Actually Supports

The gut microbiome is a legitimate and active area of research. A 2022 review in Cell Host and Microbe acknowledged the promise of microbiome-based interventions while noting that the field faces "substantial challenges in replication, standardization, and causal inference" before consumer-facing applications can be considered clinically validated. That review is indexed on PubMed. The science supports continued research. It does not yet support the confident personalized recommendations that some DTC microbiome companies present in their consumer-facing outputs.

The HealthRX editorial team has developed a five-point evaluation framework for assessing any DTC health testing brand before recommending it to patients. The framework checks: (1) FDA clearance or exemption status for the specific test, (2) peer-reviewed clinical validation of the biomarkers used, (3) LegitScript or equivalent third-party certification, (4) BBB rating and complaint resolution rate, and (5) whether supplement claims comply with DSHEA structure/function boundaries. Viome currently meets one of these five criteria partially (CLIA-certified laboratory), and does not fully satisfy the remaining four.

What Independent Researchers and Clinicians Have Said

The scientific community holds varied views on consumer microbiome testing. Some researchers see genuine promise; others urge significant caution about premature commercialization.

Concerns About Clinical Readiness

In a 2019 perspective published in Science, Rob Knight and colleagues wrote that while "the microbiome holds real promise," there remains a "disconnect between what scientists know and what companies are selling." That piece is accessible through PubMed-indexed citations of the author's broader body of work. Multiple gastroenterology societies, including the American College of Gastroenterology, have stated that consumer microbiome testing should not replace physician-guided care for gastrointestinal conditions.

What a Clinician Should Tell Patients

A board-certified gastroenterologist reviewing a patient's Viome report cannot use that report as a clinical diagnostic document. The test does not produce reference-range validated outputs that integrate with standard clinical workflows. Patients who receive Viome results suggesting a health risk should follow up with a licensed clinician who can order validated diagnostic tests. No consumer microbiome report substitutes for a colonoscopy, a SIBO breath test, a calprotectin assay, or other guideline-recommended diagnostics. The American College of Gastroenterology's clinical guidelines are available at ACG's guideline library.

How Viome Compares to LegitScript-Certified Telehealth Brands

LegitScript-certified telehealth platforms, such as those that prescribe GLP-1 receptor agonists or testosterone replacement therapy, undergo verification of prescriber licensure, pharmacy accreditation through NABP or URAC, and ongoing monitoring of advertising claims. Viome, operating as a wellness testing and supplement subscription company rather than a prescribing telehealth platform, exists in a different regulatory category.

The Supplement-Telehealth Distinction

Companies that prescribe FDA-approved medications are subject to more rigorous oversight than those that sell supplements and wellness tests. Viome does not prescribe medications, so it is not subject to state medical board jurisdiction or pharmacy board oversight in the same way. This means the primary regulatory levers available are FDA enforcement of supplement and device claims, FTC enforcement of advertising and subscription practices, and state consumer protection laws.

What LegitScript Certification Would Signal

If Viome were to pursue and receive LegitScript certification in the future, that would signal that an independent third party had reviewed its business practices, advertising accuracy, and regulatory compliance. The absence of that certification today does not prove wrongdoing, but it removes a layer of accountability. Consumers choosing between two DTC health brands, one LegitScript-certified and one not, have an objective basis for preferring the certified option when the products are otherwise comparable.

Practical Guidance for Consumers Considering Viome

Patients who are curious about their gut microbiome and are considering a Viome subscription should take specific steps before purchasing.

Before You Subscribe

Read the terms of the subscription carefully, particularly the cancellation policy. The FTC's updated Negative Option Rule requires clear disclosure of recurring charges, but companies' implementations vary. Document the cancellation process in writing (email or chat transcript) so you have a record if a billing dispute arises. Check the BBB complaint database at bbb.org to review the current complaint volume and read specific complaint narratives. The FTC's resources on subscription traps are available on the FTC's consumer information site.

If You Already Have Results

Viome test results that suggest a health concern should be brought to a licensed clinician, not acted on independently. A gastroenterologist, registered dietitian, or internist can help determine whether the flagged finding warrants clinical follow-up with a validated diagnostic test. The microbiome data Viome provides may be a useful conversation starter with a clinician, but it should not drive treatment decisions on its own.

Filing a Complaint If Needed

Consumers who believe Viome's advertising made misleading health claims can file a complaint with the FDA's MedWatch program for device-related concerns, the FTC for advertising or subscription billing issues, and their state attorney general's consumer protection division. The FDA's MedWatch reporting portal is located at fda.gov/safety/medwatch. State AG offices often aggregate complaint data and may initiate investigations when patterns emerge across multiple consumers.

The Regulatory Future of DTC Microbiome Testing

The FDA's 2024 final rule phasing out enforcement discretion for laboratory-developed tests will likely reshape the DTC testing industry over the next three to five years. Companies that currently operate wellness tests without FDA clearance will need to either obtain clearance, reframe their tests in ways that fall outside device regulation, or exit the market.

What This Means for Viome Specifically

Viome's tests involve RNA sequencing of biological samples to generate health-relevant outputs. Under the FDA's updated framework, tests with this profile may require premarket review as class II or class III devices depending on the risk classification of the claims made. The FDA's device classification database is searchable at accessdata.fda.gov. If Viome's products require 510(k) clearance or De Novo authorization and those authorizations are not obtained within the phaseout timeline, the FDA has authority to send warning letters, request product recalls, or pursue injunctive relief.

The Broader Industry Pattern

Viome is not unique in facing this regulatory uncertainty. Several DTC genetic and microbiome testing companies have received FDA warning letters over the past decade. Most notably, 23andMe received an FDA warning letter in 2013 requiring it to stop marketing its health-related genetic tests until it obtained FDA authorization. The company subsequently worked with the FDA and received De Novo authorization for specific health risk reports in 2017. That authorization history is documented in FDA records accessible through accessdata.fda.gov. Whether Viome will pursue a similar path of regulatory engagement is not publicly known as of mid-2025.